|
|
Bill |
|
Jackson, Ph.D |
|
Founder & CEO |
Base Pair Biotechnologies, Inc. |
https://proventainternational.com/wp-content/uploads/2024/11/Bill-Jackson-1.jpg |
As CEO of BasePair Biotechnologies, Bill has been leading the development and commercialization of aptamer-based diagnostics and therapeutics since 2012. In addition to private capital, Dr. Jackson has also secured significant non-dilutive funding through government grants and contracts as well as revenue from earlystage products and services. He has served as principal investigator on more than 20 federally funded research projects and established collaborations with clinicians and researchers at world-class research institutions and universities. Bill also serves frequently as a panel reviewer regarding molecular diagnostics and related tools, environmental monitoring, and biodefense. His stated mission is to leverage the potential of aptamers to create innovative solutions for global health and environmental challenges, and to advance the field of aptamer science and technology. |
|
|
Bishnu |
|
Nayak |
|
Senior Director/Site Head |
Neologics Bio |
https://proventainternational.com/wp-content/uploads/2024/03/Bishnu-Nayak-Neologics-Bio.jpg |
Bishnu is an immunologist by training with more than 15-years of experience in drug discovery research. His expertise include target identification, validation, translational research, MoA studies, and validation of therapeutic concepts, both in vitro and in vivo. He worked extensively with small molecules and biologics, particularly in immuno-oncology and inflammation space. From target discovery to lead identification and preclinical validation, he contributed at large pharmaceutical companies like Novartis and AbbVie (Pharmacyclics), mediumsized firms like AnaptysBio, and small biotechs like HealthTell and NeologicsBio. Currently, he serves as Senior Director and Site Head at Neologics Bioscience, San Diego. |
|
|
Elliott |
|
J. Brecht |
|
Director of Business Development |
SAI Life |
https://proventainternational.com/wp-content/uploads/2025/10/Elliott-Brecht.jpg |
|
|
|
Fernando |
|
Aleman |
|
Founder and CSO |
Navega Therapeutics |
https://proventainternational.com/wp-content/uploads/2020/04/Fernando-Aleman.jpg |
Fernando Aleman obtained his PharmD at University of Granada and his PhD at University of Murcia, both in Spain. He then performed postdoctoral studies at the University of California San Diego and the Scripps Research Institute in molecular biology, transcription factors and immunology. Dr. Aleman is the co-founder, president and current Chief Scientific Officer of Navega Therapeutics where he has secured more than $8M in non-dilutive funding. He leverages his pharmaceutical, research and industry background to provide medical oversight and strategic direction for all development activities, define regulatory strategy and business development activities, and serves as the pharmaceutical point of contact for external stakeholders.
|
|
|
Igor |
|
O. Nasonkin |
|
CEO |
Phythera Therapeutics |
https://proventainternational.com/wp-content/uploads/2025/06/Igor-O.-Nasonkin.jpg |
Igor Nasonkin is a Founder, Director, and Principal Investigator, with 9 years in industry (Phythera Therapeutics, Lineage Cell Therapeutics, Biotime, Bresagen) and 24 years in academia (UPitt, NIH, JHU, MIT, UM, UBC). He specialized in small molecule-based therapies modulating neurodegenerative diseases and cancer, botanical-based drugs for cancer therapeutics, cell & gene therapies (retina, brain), stem cell-based therapies, and building new projects and teams from the ground up. Igor has extensive experience in building and leading several productive & cohesive research teams, conceptualizing new ideas and research directions, grant writing (NIH, DOD, CIRM, foundation grants), manuscript writing, drafting patent applications, sponsored projects agreements, and business plans. He has written for a variety of Scientific reviewers (several journals), while being a member of the Editorial Board (several journals). His successfully funded SBIR grants include: 5R44EY027654 09/30/2017- 5/31/2019; 3 R44 EY 027654-02 S1 06/01/2019-05/31/2020 |
|
|
Klaus |
|
Simonsen |
|
Vice President, Head of External Research & Innovation |
Lundbeck |
https://proventainternational.com/wp-content/uploads/2021/04/Klaus-Simonsen.jpg |
Klaus Baek Simonsen, Ph.D., is Vice President and Head of External Research and Innovation at Lundbeck. Since joining Lundbeck in 2005 he has held several Drug Discovery leadership roles. Most recently as Vice President and Site Head of Lundbeck La Jolla Research Center in San Diego. He has more than 20 years’ experience in drug discovery and medicinal chemistry, which has resulted in the nomination of more than 25 drug candidates to preclinical and clinical development for many different target classes and published more than 70 scientific papers and patents. Dr. Simonsen gained his first drug Discovery experience at Anadys Pharmaceutical, a small Biotech in San Diego that he joined after his Post doc. at the Scripps Research Institute |
|
|
Mehran |
|
Moghaddam |
|
CEO |
OROX Biosciences, Inc. |
https://proventainternational.com/wp-content/uploads/2025/06/Mehran-F.-Moghaddam.jpg |
|
|
|
Moorthy |
|
Palanki |
|
Program Director / Professor, Biotechnology |
California State University San Marcos |
https://proventainternational.com/wp-content/uploads/2025/10/Moorthy-Palanki.jpg |
|
|
|
Sang |
|
Van |
|
CEO |
Paramita Therapeutics, Inc. |
https://proventainternational.com/wp-content/uploads/2025/09/Sang-Van.jpg |
|
|
|
Sudar |
|
Alagarsamy |
|
Executive Director Program Management |
Arrowhead Pharmaceuticals |
https://proventainternational.com/wp-content/uploads/2025/05/Sudar-Alagarsamy.jpg |
|
|
|
Yoshi |
|
Satoh |
|
VP of Chemistry |
Rev Therapeutics |
https://proventainternational.com/wp-content/uploads/2024/01/Yoshi-Satoh.jpg |
Dr. Satoh is an experienced and successful drug hunter/medicinal chemist who led discovery efforts of multiple molecules into development at Novartis and Celgene. He has an established track record for medicinal chemistry optimization of small molecule leads to high quality clinical candidates for cardiovascular, inflammation/ immunology, and oncology applications, and is intimately familiar with all aspects of discovery, including structural biology, biochemistry, cellular and in vivo pharmacology, DMPK, discovery and non-clinical safety, process chemistry, and CMC issues. Dr. Satoh published more than 50 articles/presentations/books/ reviews, and is an inventor of 16 patents. He currently serves as VP of Chemistry at Rev-Therapeutics, Inc. |
|
|
Zev |
|
Wisotsky |
|
Director, Drug Discovery New Modality Solutions |
Revvity Signals |
https://proventainternational.com/wp-content/uploads/2024/04/Zev-Wisotsky.jpg |
Zev Wisotsky is Director of Drug Discovery Informatics at Revvity Signals. His scientific training and research background includes neuroscience, biochemistry, molecular biology and drug discovery. He has spent more than eight years in software in go-to-market teams across industries with a heavy focus on biopharma/biotech R&D. |
|
|
Zhiyong |
|
Wang |
|
Founder and Chief Scientific Officer |
Venquis Therapeutics |
https://proventainternational.com/wp-content/uploads/2025/09/Zhiyong-Wang-1.jpg |
Zhiyong Wang, PhD, is Founder and CSO of Venquis Therapeutics. Dr. Wang is working with the founding team of Venquis to discover and develop small molecule direct degraders. Zhiyong has led the successful development of degraders for PI3Ka and KRAS cancer driver mutants and established a positive selection platform for HTS. Dr. Wang got his PhD for molecular immunology at UT Southwestern Medical Center and train with Dr. Tony Hunter at Salk, he then went to industry to start drug hunting career. |
Medicinal Chemistry
Drug Discovery Biology
Hard Rock Hotel San Diego
Payment Securely powered by stripe
